Michael Kauffman MD PhD has spent the last 28 years in the pharmaceutical industry. He played major leadership roles in the development and approval of three cancer drugs: Velcade®, Kyprolis®, and Xpovio®. He is the lead director or chairman of the board for Verastem Oncology, BiVictriX, and Parthenon Therapeutics, and a board member at Kezar Life Sciences and Adicet Bio. Dr. Kauffman was co-founder and previously served as Chief Executive Officer of Karyopharm, where he guided the company’s transition from a discovery-stage biotechnology company to a commercial-stage organization with the global approvals of XPOVIO®, and served as Senior Medical Advisor thereafter. Dr. Kauffman was also the previous Chief Medical Officer of Onyx Pharmaceuticals Inc. where he lead the development and approval of Kyprolis® and used to serve as President and Chief Executive Officer of EPIX Pharmaceuticals, Inc. (previously Predix Pharmaceuticals, Inc.). Dr. Kauffman received his M.D. and Ph.D. from Johns Hopkins Medical School, trained at Beth Israel and Massachusetts General Hospitals in Boston, and is board certified in Internal Medicine.